CYTK Q4 2020 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena

CYTKCytokinetics, Incorporated

$8B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+29.0% YoY

Gross Profit

-$22M-334.7% margin

Operating Income

-$36M-541.6% margin

Net Income

-$44M-653.5% margin

EPS (Diluted)

$-0.62

QoQ Revenue Growth

-83.9%

Cash Flow

Operating Cash Flow

$52M

Free Cash Flow

$46M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$534M

Total Liabilities

$420M

Stockholders' Equity

$113M

Cash & Equivalents

$83M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$5M	+29.0%
Gross Profit	-$22M	-$13M	-71.5%
Operating Income	-$36M	-$24M	-53.6%
Net Income	-$44M	-$31M	-43.4%

Revenue Segments

Research And Development

$4M70%

Research And Development Milestone Grant And Other Revenues Net

$2M30%